Study Title: Phase 3b, Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring (VR) and Oral TRUVADA Use in Pregnancy
MTN-042 is a Phase 3b, open-label, multi-site, randomized (2:1 in Cohorts 1-2 and 4:1 in Cohort 3) trial designed to assess the safety, adherence and acceptability profiles of the 25 mg dapivirine VR and Truvada (200 mg FTC/300 mg TDF) oral tablet when used during pregnancy. Approximately 550 healthy, HIV-uninfected women who are 18-45 years of age, pregnant with a single child, and willing to use study product during pregnancy will be enrolled in MTN-042 along with their newborn infants. Participants will be enrolled into one of three cohorts, with onset of dosing period for each cohort to occur within the following gestational age (GA) ranges:
Cohort 1: 36 0/7 weeks – 37 6/7 weeks 150 women
Cohort 2: 30 0/7 weeks – 35 6/7 weeks 150 women
Cohort 3: 12 0/7 weeks – 29 6/7 weeks 250 women
The primary objectives are to describe the maternal and infant safety profile and the pregnancy outcomes associated with study product exposure during pregnancy. The study will also assess pregnancy complications and infant levels of study drugs associate with product exposure as well as adherence to and acceptability of open label use of the dapivirine VR and oral Truvada in pregnant women. The three cohorts will be enrolled sequentially, with pauses between cohorts to review interim safety data. Enrolled maternal participants will be on study product for up to 30 weeks and followed up for up to 36 weeks, depending on GA at enrollment and timing of pregnancy outcome. Enrolled newborn participants will be followed up for approximately 1 year. Accrual of Cohort 1 was completed on April 13, 2021. Enrollment to Cohort 2 will continue after the interim safety review of Cohort 1.
Location: Zengeza CRS